Christopher P. Wardell
High Impact
Assistant Professor
faculty
Biomedical Informatics, College of Medicine
36 h-index
164 pubs
7,586 cited
Research Areas
Biography and Research Information
OverviewAI-generated summary
Christopher P. Wardell is an Assistant Professor in Biomedical Informatics at the University of Arkansas for Medical Sciences. His research focuses on understanding the genomic and transcriptomic underpinnings of cancer, particularly multiple myeloma and glioblastoma. He investigates the molecular mechanisms driving cancer evolution, the impact of structural variants and mutations on clinical outcomes, and the development of resistance to therapeutic agents.
Wardell's work involves developing and applying computational pipelines for analyzing next-generation sequencing data, including somatic mutation detection and comparative transcriptomics. He has explored the molecular features of smoldering myeloma and high-risk transcriptional profiles in multiple myeloma, identifying acquired features that emerge with disease progression and relapse. His research also extends to identifying personalized treatment strategies through functional precision medicine approaches, combining transcriptomics with organoid modeling.
His scholarship metrics include an h-index of 36, with over 163 publications and 7,505 citations. Wardell collaborates with researchers at the University of Arkansas for Medical Sciences, including Michael Bauer, Cody Ashby, Michael Rutherford, and Murat Gökden, with whom he has co-authored multiple publications.
Metrics
- h-index: 36
- Publications: 164
- Citations: 7,586
Selected Publications
-
Applying computational modelling to a high-risk multiple myeloma data set to create novel risk stratification groupings (2025)
-
Healing of lytic lesions and restoration of bone health in multiple myeloma through sclerostin inhibition (2025)
-
Evaluating Skellytour for Automated Skeleton Segmentation from Whole-Body CT Images (2025)
-
Long-read sequencing for brain tumors (2024)
-
Abstract 953: Integration of functional precision medicine assay for high grade glioma management: A single institution experience (2024)
-
Intracranial hematolymphoid malignancies: A case series with molecular characterization (2023)
-
Science and Tools of Radiomics for Radiation Oncology (2023)
-
An advanced molecular medicine case report of a rare human tumor using genomics, pathomics, and radiomics (2023)
-
The Impact of Autologous Stem Cell Transplantation on the Genetics of High-Risk Relapsed Multiple Myeloma (2022)
-
Identification of novel long noncoding RNA with distinct expression patterns in different subtypes of multiple myeloma (2022)
-
Structural variants shape the genomic landscape and clinical outcome of multiple myeloma (2022)
-
323 Generation of a functional precision medicine pipeline which combines comparative transcriptomics and tumor organoid modeling to identify bespoke treatment strategies for glioblastoma (2022)
-
Oncogenic Mutation BRAF V600E Changes Phenotypic Behavior of THLE-2 Liver Cells through Alteration of Gene Expression (2022)
-
A Functional Precision Medicine Pipeline Combines Comparative Transcriptomics and Tumor Organoid Modeling to Identify Bespoke Treatment Strategies for Glioblastoma (2021)
-
Genomic and Transcriptomic Profiling of Brain Metastases (2021)
Grants & Funding
- TCIA Sustainment and Scalability - Platforms for Quantitative Imaging Informatics in Precision Medicine NIH Co-Investigator
- TCIA Sustainment and Scalability - Platforms for Quantitative Imaging Informatics in Precision Medicine - Year 4 - Continuation NIH/Nat. Cancer Institute Co-Investigator
Collaboration Network
Top Collaborators
Faith E. Davies
NYU Langone Health (US)
34 shared publications
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Structural variants shape the genomic landscape and clinical outcome of multiple myeloma
- Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugs
- High‐risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse
- Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups
Showing 5 of 34 shared publications
Brian A. Walker
Sylvester Comprehensive Cancer Center (US)
30 shared publications
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Structural variants shape the genomic landscape and clinical outcome of multiple myeloma
- Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugs
- High‐risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse
- Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups
Showing 5 of 30 shared publications
Gareth J. Morgan
29 shared publications
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Structural variants shape the genomic landscape and clinical outcome of multiple myeloma
- Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugs
- High‐risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse
- Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups
Showing 5 of 29 shared publications
Walter M. Gregory
24 shared publications
- The Impact of gain1q on Mutational Structure and Clonal Evolution in a Uniformly Treated High-Risk Series of Patients at First Relapse
- The Impact of Autologous Stem Cell Transplantation on the Genetics of High-Risk Relapsed Multiple Myeloma
- Supplementary Table 1 from Gender Disparities in the Tumor Genetics and Clinical Outcome of Multiple Myeloma
- Data from Gender Disparities in the Tumor Genetics and Clinical Outcome of Multiple Myeloma
- Data from Gender Disparities in the Tumor Genetics and Clinical Outcome of Multiple Myeloma
Showing 5 of 24 shared publications
Graham Jackson
Newcastle University (GB)
19 shared publications
- The Impact of gain1q on Mutational Structure and Clonal Evolution in a Uniformly Treated High-Risk Series of Patients at First Relapse
- The Impact of Autologous Stem Cell Transplantation on the Genetics of High-Risk Relapsed Multiple Myeloma
- Supplementary Table 1 from Mapping of Chromosome 1p Deletions in Myeloma Identifies <i>FAM46C</i> at 1p12 and <i>CDKN2C</i> at 1p32.3 as Being Genes in Regions Associated with Adverse Survival
- Supplementary Table 3 from Mapping of Chromosome 1p Deletions in Myeloma Identifies <i>FAM46C</i> at 1p12 and <i>CDKN2C</i> at 1p32.3 as Being Genes in Regions Associated with Adverse Survival
- Supplementary Table 2 from Mapping of Chromosome 1p Deletions in Myeloma Identifies <i>FAM46C</i> at 1p12 and <i>CDKN2C</i> at 1p32.3 as Being Genes in Regions Associated with Adverse Survival
Showing 5 of 19 shared publications
Kevin Boyd
18 shared publications
- Supplementary Table 1 from Gender Disparities in the Tumor Genetics and Clinical Outcome of Multiple Myeloma
- Data from Gender Disparities in the Tumor Genetics and Clinical Outcome of Multiple Myeloma
- Data from Gender Disparities in the Tumor Genetics and Clinical Outcome of Multiple Myeloma
- Supplementary Methods, References, Legends for Table 1 and Figure 1 from Gender Disparities in the Tumor Genetics and Clinical Outcome of Multiple Myeloma
- Supplementary Table 2 from Gender Disparities in the Tumor Genetics and Clinical Outcome of Multiple Myeloma
Showing 5 of 18 shared publications
Fiona M. Ross
18 shared publications
- Supplementary Table 1 from Gender Disparities in the Tumor Genetics and Clinical Outcome of Multiple Myeloma
- Data from Gender Disparities in the Tumor Genetics and Clinical Outcome of Multiple Myeloma
- Data from Gender Disparities in the Tumor Genetics and Clinical Outcome of Multiple Myeloma
- Supplementary Methods, References, Legends for Table 1 and Figure 1 from Gender Disparities in the Tumor Genetics and Clinical Outcome of Multiple Myeloma
- Supplementary Table 2 from Gender Disparities in the Tumor Genetics and Clinical Outcome of Multiple Myeloma
Showing 5 of 18 shared publications
Laura Chiecchio
18 shared publications
- Supplementary Table 1 from Gender Disparities in the Tumor Genetics and Clinical Outcome of Multiple Myeloma
- Data from Gender Disparities in the Tumor Genetics and Clinical Outcome of Multiple Myeloma
- Data from Gender Disparities in the Tumor Genetics and Clinical Outcome of Multiple Myeloma
- Supplementary Methods, References, Legends for Table 1 and Figure 1 from Gender Disparities in the Tumor Genetics and Clinical Outcome of Multiple Myeloma
- Supplementary Table 2 from Gender Disparities in the Tumor Genetics and Clinical Outcome of Multiple Myeloma
Showing 5 of 18 shared publications
Gian Paolo Dagrada
18 shared publications
- Supplementary Table 1 from Gender Disparities in the Tumor Genetics and Clinical Outcome of Multiple Myeloma
- Data from Gender Disparities in the Tumor Genetics and Clinical Outcome of Multiple Myeloma
- Data from Gender Disparities in the Tumor Genetics and Clinical Outcome of Multiple Myeloma
- Supplementary Methods, References, Legends for Table 1 and Figure 1 from Gender Disparities in the Tumor Genetics and Clinical Outcome of Multiple Myeloma
- Supplementary Table 2 from Gender Disparities in the Tumor Genetics and Clinical Outcome of Multiple Myeloma
Showing 5 of 18 shared publications
Zoë J. Konn
18 shared publications
- Supplementary Table 1 from Gender Disparities in the Tumor Genetics and Clinical Outcome of Multiple Myeloma
- Data from Gender Disparities in the Tumor Genetics and Clinical Outcome of Multiple Myeloma
- Data from Gender Disparities in the Tumor Genetics and Clinical Outcome of Multiple Myeloma
- Supplementary Methods, References, Legends for Table 1 and Figure 1 from Gender Disparities in the Tumor Genetics and Clinical Outcome of Multiple Myeloma
- Supplementary Table 2 from Gender Disparities in the Tumor Genetics and Clinical Outcome of Multiple Myeloma
Showing 5 of 18 shared publications
William Tapper
18 shared publications
- Supplementary Table 1 from Gender Disparities in the Tumor Genetics and Clinical Outcome of Multiple Myeloma
- Data from Gender Disparities in the Tumor Genetics and Clinical Outcome of Multiple Myeloma
- Data from Gender Disparities in the Tumor Genetics and Clinical Outcome of Multiple Myeloma
- Supplementary Methods, References, Legends for Table 1 and Figure 1 from Gender Disparities in the Tumor Genetics and Clinical Outcome of Multiple Myeloma
- Supplementary Table 2 from Gender Disparities in the Tumor Genetics and Clinical Outcome of Multiple Myeloma
Showing 5 of 18 shared publications
Cody Ashby
University of Arkansas for Medical Sciences
15 shared publications
In database
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Structural variants shape the genomic landscape and clinical outcome of multiple myeloma
- Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugs
- FiNGS: high quality somatic mutations using filters for next generation sequencing
- High‐risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse
Showing 5 of 15 shared publications
Eileen M. Boyle
Centre National de la Recherche Scientifique (FR)
12 shared publications
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Structural variants shape the genomic landscape and clinical outcome of multiple myeloma
- High‐risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse
- Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups
- Supplementary material from The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma
Showing 5 of 12 shared publications
Michael Bauer
11 shared publications
In database
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Structural variants shape the genomic landscape and clinical outcome of multiple myeloma
- FiNGS: high quality somatic mutations using filters for next generation sequencing
- High‐risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse
- Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups
Showing 5 of 11 shared publications
Bart Barlogie
Hôpital Claude Huriez
11 shared publications
In database
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- High‐risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse
- Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups
- Supplementary material from The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma
- Supplementary Data from <i>BRAF</i> and <i>DIS3</i> Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma
Showing 5 of 11 shared publications
Similar Researchers
Based on overlapping research topics
Fritz Van Rhee
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer Genomics and Diagnostics
Bioinformatics and Genomic Networks
Michael Gallagher
University of Central Arkansas
Cancer Genomics and Diagnostics
Genomics and Phylogenetic Studies
Cancer-related molecular mechanisms research
Shiv Srivastava
University of Arkansas for Medical Sciences
Cancer Genomics and Diagnostics
Bioinformatics and Genomic Networks
Genomics and Phylogenetic Studies
Sarah K. Johnson
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer Genomics and Diagnostics
Genomics and Phylogenetic Studies
Sarah K. Johnson
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Bioinformatics and Genomic Networks
Genomics and Phylogenetic Studies
Jason Muesse
University of Arkansas for Medical Sciences
Cancer Genomics and Diagnostics
Bioinformatics and Genomic Networks
Genomics and Phylogenetic Studies